NZ331163A - Composition comprising interleukin-1 inhibitor and hydrogel ester (hyaluronan) for treating inflammatory diseases - Google Patents
Composition comprising interleukin-1 inhibitor and hydrogel ester (hyaluronan) for treating inflammatory diseasesInfo
- Publication number
- NZ331163A NZ331163A NZ331163A NZ33116397A NZ331163A NZ 331163 A NZ331163 A NZ 331163A NZ 331163 A NZ331163 A NZ 331163A NZ 33116397 A NZ33116397 A NZ 33116397A NZ 331163 A NZ331163 A NZ 331163A
- Authority
- NZ
- New Zealand
- Prior art keywords
- hyaluronan
- composition
- inflammatory diseases
- interleukin
- inhibitor
- Prior art date
Links
- 150000002148 esters Chemical class 0.000 title abstract 3
- 239000000017 hydrogel Substances 0.000 title abstract 3
- 102000000589 Interleukin-1 Human genes 0.000 title abstract 2
- 108010002352 Interleukin-1 Proteins 0.000 title abstract 2
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 title abstract 2
- 229940099552 hyaluronan Drugs 0.000 title abstract 2
- 229920002674 hyaluronan Polymers 0.000 title abstract 2
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- -1 hyaluronan Chemical class 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 102000009634 interleukin-1 receptor antagonist activity proteins Human genes 0.000 abstract 1
- 108040001669 interleukin-1 receptor antagonist activity proteins Proteins 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1141996P | 1996-02-09 | 1996-02-09 | |
| US3278996P | 1996-12-06 | 1996-12-06 | |
| US3624197P | 1997-01-23 | 1997-01-23 | |
| US08/798,414 US6096728A (en) | 1996-02-09 | 1997-02-07 | Composition and method for treating inflammatory diseases |
| PCT/US1997/002131 WO1997028828A1 (en) | 1996-02-09 | 1997-02-10 | Composition comprising interleukin-1 inhibitor and controlled release polymer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ331163A true NZ331163A (en) | 2000-07-28 |
Family
ID=27486083
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ503548A NZ503548A (en) | 1996-02-09 | 1997-02-10 | A fusion protein comprising an IL-1ra receptor antagonist with a constant domain of human immunoglobulin at the carboxy terminus |
| NZ331163A NZ331163A (en) | 1996-02-09 | 1997-02-10 | Composition comprising interleukin-1 inhibitor and hydrogel ester (hyaluronan) for treating inflammatory diseases |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ503548A NZ503548A (en) | 1996-02-09 | 1997-02-10 | A fusion protein comprising an IL-1ra receptor antagonist with a constant domain of human immunoglobulin at the carboxy terminus |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0904112B1 (enExample) |
| JP (2) | JP4344404B2 (enExample) |
| KR (1) | KR20040010739A (enExample) |
| CN (1) | CN1215340A (enExample) |
| AT (1) | ATE448797T1 (enExample) |
| AU (1) | AU724960C (enExample) |
| BR (1) | BR9707325A (enExample) |
| CA (2) | CA2539273C (enExample) |
| CZ (1) | CZ299025B6 (enExample) |
| DE (1) | DE69739656D1 (enExample) |
| EA (2) | EA200000825A1 (enExample) |
| ES (1) | ES2334726T3 (enExample) |
| HU (1) | HU230160B1 (enExample) |
| IL (1) | IL125552A0 (enExample) |
| MX (1) | MX9806191A (enExample) |
| NO (1) | NO983543L (enExample) |
| NZ (2) | NZ503548A (enExample) |
| SK (1) | SK288144B6 (enExample) |
| WO (1) | WO1997028828A1 (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2312179T3 (es) | 1996-12-06 | 2009-02-16 | Amgen Inc. | Terapia combinada que utiliza un inhibidor del il-1 para el tratamiento de enfermedades mediadas por el il-1. |
| US7488590B2 (en) | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| DK1783222T3 (da) | 1998-10-23 | 2012-07-09 | Kirin Amgen Inc | Dimere trombopoietiske peptidomimetika, der binder til MPL-receptor og har trombopoietisk aktivitet |
| AT406054B (de) * | 1998-11-04 | 2000-02-25 | Andreas Bernkop-Schnuerch | Verfahren zur verbesserung der mucoadhäsion von polymeren sowie deren herstellung und verwendung |
| DK1203583T3 (da) * | 1999-06-21 | 2006-04-18 | Santen Pharmaceutical Co Ltd | Afhjælpende midler til arthrosis deformans |
| RU2271825C2 (ru) * | 1999-07-21 | 2006-03-20 | Омерос Корпорейшн | Растворы и способы ингибирования боли, воспаления и разрушения хряща |
| US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
| AU2001259432B2 (en) * | 2000-05-03 | 2005-04-21 | Amgen Inc. | Modified peptides, comprising an FC domain, as therapeutic agents |
| US7324635B2 (en) | 2000-05-04 | 2008-01-29 | Telemaze Llc | Branch calling and caller ID based call routing telephone features |
| EP1712239A3 (en) * | 2000-05-12 | 2007-08-22 | Immunex Corporation | Interleukin-1 inhibitors in the treatment of diseases |
| US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| JP4340062B2 (ja) | 2000-10-12 | 2009-10-07 | ジェネンテック・インコーポレーテッド | 粘度の減少した濃縮タンパク質製剤 |
| US7087224B2 (en) | 2000-10-31 | 2006-08-08 | Amgen Inc. | Method of treating anemia by administering IL-1ra |
| NZ530765A (en) | 2001-06-26 | 2006-11-30 | Amgen Fremont Inc | Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases |
| US6818613B2 (en) * | 2001-11-07 | 2004-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | Aqueous sustained-release formulations of proteins |
| CA2472188C (en) * | 2002-01-18 | 2011-06-21 | Control Delivery Systems, Inc. | Polymeric gel system for the controlled delivery of codrugs |
| CA2485166A1 (en) | 2002-05-21 | 2003-12-04 | Amgen Inc. | Substituted pyrimidinone and pyridinone compounds |
| SG2013096847A1 (en) | 2002-09-06 | 2017-05-30 | Medarex Llc | Therapeutic human anti-il-1r1 monoclonal antibody |
| US8273347B2 (en) | 2003-05-13 | 2012-09-25 | Depuy Spine, Inc. | Autologous treatment of degenerated disc with cells |
| US7344716B2 (en) | 2003-05-13 | 2008-03-18 | Depuy Spine, Inc. | Transdiscal administration of specific inhibitors of pro-inflammatory cytokines |
| US7429378B2 (en) | 2003-05-13 | 2008-09-30 | Depuy Spine, Inc. | Transdiscal administration of high affinity anti-MMP inhibitors |
| US7553827B2 (en) | 2003-08-13 | 2009-06-30 | Depuy Spine, Inc. | Transdiscal administration of cycline compounds |
| US8361467B2 (en) * | 2003-07-30 | 2013-01-29 | Depuy Spine, Inc. | Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints |
| US8895540B2 (en) | 2003-11-26 | 2014-11-25 | DePuy Synthes Products, LLC | Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor |
| LT1729810T (lt) * | 2004-04-02 | 2018-11-26 | Swedish Orphan Biovitrum Ab (Publ) | Il-1ra agregacijos sumažinimo būdas |
| MX2007003320A (es) | 2004-09-24 | 2007-05-18 | Amgen Inc | Moleculas fc modificadas. |
| CA2590159C (en) * | 2004-12-30 | 2011-07-12 | Genzyme Corporation | Regimens for intra-articular viscosupplementation |
| EP3725299A1 (en) * | 2005-06-24 | 2020-10-21 | Duke University | A direct drug delivery system based on thermally responsive biopolymers |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| TW200736277A (en) | 2005-11-14 | 2007-10-01 | Amgen Inc | RANKL antibody-PTH/PTHrP chimeric molecules |
| US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
| GB0708376D0 (en) | 2007-05-01 | 2007-06-06 | Alligator Bioscience Ab | Novel polypeptides and uses thereof |
| WO2009062339A1 (en) | 2007-11-14 | 2009-05-22 | General Regeneratives, Ltd. | Methods of using interleukin-1 receptor antagonist as a myeloprotective agent |
| US8986696B2 (en) | 2007-12-21 | 2015-03-24 | Depuy Mitek, Inc. | Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints |
| EP2259774B1 (en) | 2008-02-27 | 2012-12-12 | Biomet Biologics, LLC | Methods and compositions for delivering interleukin-1 receptor antagonist |
| KR200451958Y1 (ko) * | 2008-10-09 | 2011-01-21 | (주)에이치시티 | 모바일기기용 카드형 안테나장치 |
| SG174258A1 (en) | 2009-03-06 | 2011-10-28 | Genentech Inc | Antibody formulation |
| US20110052561A1 (en) * | 2009-08-27 | 2011-03-03 | Biomet Biologics,LLC | Osteolysis treatment |
| TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
| CN101690801B (zh) | 2009-10-26 | 2012-08-01 | 上海交通大学 | 白细胞介素-1受体拮抗剂的用途及其药物组合物 |
| DE202009017772U1 (de) | 2009-12-10 | 2011-04-21 | Orthogen Ag | Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid |
| MX341578B (es) * | 2011-02-08 | 2016-08-25 | Abbvie Inc | Tratamiento de la osteoartritis y del dolor. |
| HRP20160928T1 (hr) | 2011-02-11 | 2016-10-07 | Swedish Orphan Biovitrum Ab (Publ) | Farmaceutske kompozicije koje sadrže anakinra bez citrata |
| WO2013016220A1 (en) | 2011-07-22 | 2013-01-31 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
| CN103781473A (zh) | 2011-09-02 | 2014-05-07 | 诺维信生物制药丹麦公司 | 包含用于持续药物释放的透明质酸的口服配制品 |
| US9758806B2 (en) | 2013-03-15 | 2017-09-12 | Biomet Biologics, Llc | Acellular compositions for treating inflammatory disorders |
| US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
| US9878011B2 (en) | 2013-03-15 | 2018-01-30 | Biomet Biologics, Llc | Treatment of inflammatory respiratory disease using biological solutions |
| US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
| US20140271589A1 (en) | 2013-03-15 | 2014-09-18 | Biomet Biologics, Llc | Treatment of collagen defects using protein solutions |
| AU2014333953C1 (en) * | 2013-10-08 | 2020-06-25 | Ascendis Pharma A/S | Hydrogel-linked IL-1ra prodrug |
| US20160000936A1 (en) | 2014-06-10 | 2016-01-07 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
| CZ309295B6 (cs) * | 2015-03-09 | 2022-08-10 | Contipro A.S. | Samonosný, biodegradabilní film na bázi hydrofobizované kyseliny hyaluronové, způsob jeho přípravy a použití |
| US10041044B2 (en) | 2016-07-29 | 2018-08-07 | Trustees Of Boston University | Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development |
| CN110891611B (zh) | 2017-03-22 | 2024-03-29 | 阿森迪斯制药公司 | 水凝胶交联透明质酸前药组合物和方法 |
| CN112584823A (zh) * | 2018-06-22 | 2021-03-30 | 纽约哥伦比亚大学理事会 | 用于治疗颞颌关节退化的缓释组成物及方法 |
| EP3836954B1 (en) | 2018-08-13 | 2025-05-07 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
| WO2020112853A1 (en) * | 2018-11-28 | 2020-06-04 | Genascence Corporation | Methods and compositions for treating osteoarthritis |
| CA3147909A1 (en) | 2019-08-08 | 2021-02-11 | Avidence Therapeutics, Inc. | Microsphere-based injectible celecoxib formulation |
| US20250283174A1 (en) | 2022-05-16 | 2025-09-11 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stem cells induced by chronic inflammation |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| JPH02503867A (ja) | 1988-04-15 | 1990-11-15 | プロテイン デザイン ラブズ インコーポレーテッド | Ｉｌ‐２レセプター特異的キメラ抗体 |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| ES2238070T3 (es) | 1989-04-21 | 2005-08-16 | Amgen Inc. | Receptor del tnf, proteina ligante del tnf y adn codante para estos. |
| IL95031A (en) | 1989-07-18 | 2007-03-08 | Amgen Inc | Method for the production of a human recombinant tumor necrosis factor inhibitor |
| CA2485553A1 (en) | 1989-09-05 | 1991-03-21 | Immunex Corporation | Tumor necrosis factor - .alpha. and - .beta. receptors |
| AU649245B2 (en) * | 1990-04-02 | 1994-05-19 | Amgen, Inc. | Methods for treating interleukin-1 mediated diseases |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US6458360B1 (en) | 1990-04-25 | 2002-10-01 | The Johns Hopkins University | Soluble complement regulatory molecules |
| WO1991017184A1 (en) | 1990-04-27 | 1991-11-14 | The Upjohn Company | Modified interleukin-1 inhibitors |
| ATE240740T1 (de) | 1991-03-15 | 2003-06-15 | Amgen Inc | Pegylation von polypeptiden |
| NO940913L (no) * | 1993-03-26 | 1994-09-27 | Bristol Myers Squibb Co | Preparater for kontrollert frigivelse av biologisk aktiv TGF- |
| JPH06321803A (ja) * | 1993-05-17 | 1994-11-22 | Kirin Brewery Co Ltd | 水溶性ペプチドホルモンの徐放性製剤 |
| US5385887A (en) * | 1993-09-10 | 1995-01-31 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
| WO1995010298A1 (en) * | 1993-10-12 | 1995-04-20 | Mary Lake Polan | Method of contraception |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| EP0766564A4 (en) * | 1994-06-24 | 1998-09-23 | Immunex Corp | SLOW RELEASE POLYPEPTIDES COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL CONDITIONS |
| IT1269989B (it) | 1994-09-21 | 1997-04-16 | Dompe Spa | Antagonisti recettoriali di il-1 ad aumentata attivita' inibitoria |
-
1997
- 1997-02-10 HU HU9902612A patent/HU230160B1/hu unknown
- 1997-02-10 SK SK1036-98A patent/SK288144B6/sk not_active IP Right Cessation
- 1997-02-10 EA EA200000825A patent/EA200000825A1/ru unknown
- 1997-02-10 EP EP97906551A patent/EP0904112B1/en not_active Expired - Lifetime
- 1997-02-10 EA EA199800694A patent/EA001792B1/ru not_active IP Right Cessation
- 1997-02-10 KR KR10-2003-7016565A patent/KR20040010739A/ko not_active Ceased
- 1997-02-10 NZ NZ503548A patent/NZ503548A/en unknown
- 1997-02-10 CA CA2539273A patent/CA2539273C/en not_active Expired - Lifetime
- 1997-02-10 NZ NZ331163A patent/NZ331163A/xx unknown
- 1997-02-10 CN CN97193632A patent/CN1215340A/zh active Pending
- 1997-02-10 DE DE69739656T patent/DE69739656D1/de not_active Expired - Lifetime
- 1997-02-10 BR BR9707325A patent/BR9707325A/pt not_active Application Discontinuation
- 1997-02-10 AT AT97906551T patent/ATE448797T1/de not_active IP Right Cessation
- 1997-02-10 CZ CZ0237398A patent/CZ299025B6/cs not_active IP Right Cessation
- 1997-02-10 JP JP52874197A patent/JP4344404B2/ja not_active Expired - Lifetime
- 1997-02-10 IL IL12555297A patent/IL125552A0/xx unknown
- 1997-02-10 AU AU21213/97A patent/AU724960C/en not_active Expired
- 1997-02-10 ES ES97906551T patent/ES2334726T3/es not_active Expired - Lifetime
- 1997-02-10 WO PCT/US1997/002131 patent/WO1997028828A1/en not_active Ceased
- 1997-02-10 CA CA002244664A patent/CA2244664C/en not_active Expired - Lifetime
-
1998
- 1998-07-31 MX MX9806191A patent/MX9806191A/es active IP Right Grant
- 1998-07-31 NO NO983543A patent/NO983543L/no not_active Application Discontinuation
-
2007
- 2007-05-22 JP JP2007136048A patent/JP2007211027A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2244664C (en) | 2008-06-03 |
| JP4344404B2 (ja) | 2009-10-14 |
| CA2539273C (en) | 2014-02-04 |
| HUP9902612A3 (en) | 2001-11-28 |
| CN1215340A (zh) | 1999-04-28 |
| CZ299025B6 (cs) | 2008-04-02 |
| CA2244664A1 (en) | 1997-08-14 |
| DE69739656D1 (de) | 2009-12-31 |
| SK288144B6 (sk) | 2013-12-02 |
| WO1997028828A1 (en) | 1997-08-14 |
| HUP9902612A2 (hu) | 1999-11-29 |
| AU2121397A (en) | 1997-08-28 |
| NO983543D0 (no) | 1998-07-31 |
| EP0904112A1 (en) | 1999-03-31 |
| SK103698A3 (en) | 2001-01-18 |
| HU230160B1 (hu) | 2015-09-28 |
| EA200000825A1 (ru) | 2001-02-26 |
| JP2001500472A (ja) | 2001-01-16 |
| CA2539273A1 (en) | 1997-08-14 |
| EP0904112B1 (en) | 2009-11-18 |
| JP2007211027A (ja) | 2007-08-23 |
| EA001792B1 (ru) | 2001-08-27 |
| AU724960C (en) | 2002-08-15 |
| ATE448797T1 (de) | 2009-12-15 |
| MX9806191A (es) | 1998-10-31 |
| IL125552A0 (en) | 1999-03-12 |
| ES2334726T3 (es) | 2010-03-15 |
| NZ503548A (en) | 2001-09-28 |
| BR9707325A (pt) | 1999-04-13 |
| NO983543L (no) | 1998-10-08 |
| CZ237398A3 (cs) | 1999-09-15 |
| KR20040010739A (ko) | 2004-01-31 |
| AU724960B2 (en) | 2000-10-05 |
| EA199800694A1 (ru) | 1999-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ331163A (en) | Composition comprising interleukin-1 inhibitor and hydrogel ester (hyaluronan) for treating inflammatory diseases | |
| CA2031880A1 (en) | Combined anti-inflammatory agent | |
| MX9600487A (es) | Composiciones topicamente administrables que contienen derivados de acido 3-benzoilfenilacetico para el tratamiento de trastornos inflamatorios oftalmicos. | |
| CA2273240A1 (en) | Compositions and methods for treating or preventing inflammatory diseases | |
| HUP9800033A3 (en) | Compositions for the treatment of dermatological disorders and methods for their use | |
| AU3548795A (en) | Benzopyranopyrazolyl derivatives for the treatment of inflammation | |
| AU6666096A (en) | Pharmaceutical composition containing il-10 | |
| IL120317A (en) | Ciprofloxacin-hydrocortisone suspension | |
| AU2027695A (en) | Pharmaceutical composition for treating stoma-peripheral inflammation diseases | |
| FI972433A0 (fi) | Rantes-peptidi ja fragmentteja sekä tätä sisältäviä tulehduksen hoitoon soveltuvia koostumuksia | |
| AU2388895A (en) | Substituted cyclopentadienyl compounds for the treatment of inflammation | |
| MX9603596A (es) | Perfluoropolieteres o composiciones de los mismos para prevencion y tratamiento de infecciones virales topicas. | |
| AU2732597A (en) | Novel pharmaceutical compositions having steroid nitrate ester derivatives useful as anti-inflammatory drugs | |
| GR3034575T3 (en) | Steroid nitrite ester derivatives useful as anti-inflammatory drugs | |
| EP1157698A3 (en) | Treatment of inflammatory diseases with oxypurine nucleosides | |
| AU4133997A (en) | Pharmaceutical composition for the treatment of syndrome x of reaven | |
| AU7042796A (en) | Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases | |
| PT941108E (pt) | Cicatrizacao de feridas e tratamento da fibrose | |
| PT841933E (pt) | Composicoes do inibidor bowman-birk para tratamento de doencas inflamatorias | |
| AU8049098A (en) | Composition and methods for the treatment of inflammatory diseases | |
| AU3992897A (en) | Use of sulbutiamine to obtain pharmaceutical compositions useful in the treatment of certain psychomotor and psycho-intellectual disorders | |
| CA2149766A1 (en) | Rectal flunisolide compositions for treating inflammatory intestinal disorders | |
| AUPM677894A0 (en) | Modified fatty acids in the treatment of inflammation | |
| AUPM878194A0 (en) | Modified fatty acids in the treatment of inflammation | |
| AU5602898A (en) | Pharmaceutical compositions for mucolysis and treatment of inflammation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) |